Effect of IL-2 on primary hepatic carcinoma and its potential clinical value

As a T cell subsets growth factor, interleukin-2 (IL-2) can inhibit cancer cell proliferation, reduce tumorigenicity and transitivity, improve local tumor microenvironment, enhance the immunogenicity of hepatocellular carcinoma cells, reduce the load of hepatitis virus and greatly enhance the ability of anti-tumor. On the other hand, it can enhance tumor hypercoagulable state. The effect of IL-2 on primary hepatic carcinoma and its potential clinical value have a bright future. Key words: Interleukin 2; Liver neoplasms; Clinical significance